Zheng Quan Shi Bao Wang·2025-12-22 01:03Core Viewpoint - Zai Jian Pharmaceutical has submitted an application for listing on the Hong Kong Stock Exchange, with CICC as its sole sponsor, highlighting its focus on innovative therapies in oncology, autoimmune diseases, and hematology [1] Company Overview - Zai Jian Pharmaceutical is a comprehensive biopharmaceutical company dedicated to the discovery, research and development, and commercialization of innovative small molecules and biologics [1] - The company has a product portfolio that includes marketed drugs, late-stage clinical candidates, and early-stage discovery projects [1] Product Pipeline - Zai Jian Pharmaceutical currently has three marketed drugs: - Zepsu (Zepub) is the first domestically developed small molecule multi-target drug for first-line treatment of advanced liver cancer in China [1] - Zeppin (Zepping) is the first domestically developed innovative JAK inhibitor for the treatment of myelofibrosis in China [1] - Zeplin (Zepeling) is the only recombinant human thrombin developed and successfully commercialized using recombinant DNA technology in China [1]